Cargando…

A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic

In the summer of 2019, DiaSorin Molecular started designing a multiplex respiratory panel with pan-coronavirus detection as one of the planned targets. The R&D team in Gerenzano, Italy was already searching databases, performing alignments and assessing preliminary target regions for common coro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabb, Michelle M., Minnucci, Giulia, Albano, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068993/
https://www.ncbi.nlm.nih.gov/pubmed/35531327
http://dx.doi.org/10.3389/fcimb.2022.840210
_version_ 1784700340056096768
author Tabb, Michelle M.
Minnucci, Giulia
Albano, Vincenzo
author_facet Tabb, Michelle M.
Minnucci, Giulia
Albano, Vincenzo
author_sort Tabb, Michelle M.
collection PubMed
description In the summer of 2019, DiaSorin Molecular started designing a multiplex respiratory panel with pan-coronavirus detection as one of the planned targets. The R&D team in Gerenzano, Italy was already searching databases, performing alignments and assessing preliminary target regions for common coronavirus RT-PCR, including SARS and MERS-CoV. In December 2019, we were vigilant and following a cluster of pneumonia cases with undetermined etiology in Wuhan, China. As we now know, the cause of the respiratory infections was the new SARS-CoV-2 virus. DiaSorin Molecular swiftly responded in line with our heritage and company history in detecting emerging infectious diseases. Early in the pandemic and in record time, using research and development teams in both Italy and the U.S. together with the U.S. manufacturing team, we were able to develop and commercialize a new diagnostic test, Simplexa™ COVID-19 Direct, to detect SARS-CoV-2. Our unique platform allowed development of a rapid diagnostic test without the need for extraction reagents. Challenges with control materials, quarantines, clinical samples, raw materials and production were overcome and the entire company worked side by side for accelerated delivery of this assay to clinical labs in Europe, the U.S. and Canada.
format Online
Article
Text
id pubmed-9068993
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90689932022-05-05 A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic Tabb, Michelle M. Minnucci, Giulia Albano, Vincenzo Front Cell Infect Microbiol Cellular and Infection Microbiology In the summer of 2019, DiaSorin Molecular started designing a multiplex respiratory panel with pan-coronavirus detection as one of the planned targets. The R&D team in Gerenzano, Italy was already searching databases, performing alignments and assessing preliminary target regions for common coronavirus RT-PCR, including SARS and MERS-CoV. In December 2019, we were vigilant and following a cluster of pneumonia cases with undetermined etiology in Wuhan, China. As we now know, the cause of the respiratory infections was the new SARS-CoV-2 virus. DiaSorin Molecular swiftly responded in line with our heritage and company history in detecting emerging infectious diseases. Early in the pandemic and in record time, using research and development teams in both Italy and the U.S. together with the U.S. manufacturing team, we were able to develop and commercialize a new diagnostic test, Simplexa™ COVID-19 Direct, to detect SARS-CoV-2. Our unique platform allowed development of a rapid diagnostic test without the need for extraction reagents. Challenges with control materials, quarantines, clinical samples, raw materials and production were overcome and the entire company worked side by side for accelerated delivery of this assay to clinical labs in Europe, the U.S. and Canada. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9068993/ /pubmed/35531327 http://dx.doi.org/10.3389/fcimb.2022.840210 Text en Copyright © 2022 Tabb, Minnucci and Albano https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Tabb, Michelle M.
Minnucci, Giulia
Albano, Vincenzo
A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic
title A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic
title_full A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic
title_fullStr A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic
title_full_unstemmed A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic
title_short A Tale of Two Countries: DiaSorin Molecular’s Rapid Response to the COVID-19 Pandemic
title_sort tale of two countries: diasorin molecular’s rapid response to the covid-19 pandemic
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068993/
https://www.ncbi.nlm.nih.gov/pubmed/35531327
http://dx.doi.org/10.3389/fcimb.2022.840210
work_keys_str_mv AT tabbmichellem ataleoftwocountriesdiasorinmolecularsrapidresponsetothecovid19pandemic
AT minnuccigiulia ataleoftwocountriesdiasorinmolecularsrapidresponsetothecovid19pandemic
AT albanovincenzo ataleoftwocountriesdiasorinmolecularsrapidresponsetothecovid19pandemic
AT tabbmichellem taleoftwocountriesdiasorinmolecularsrapidresponsetothecovid19pandemic
AT minnuccigiulia taleoftwocountriesdiasorinmolecularsrapidresponsetothecovid19pandemic
AT albanovincenzo taleoftwocountriesdiasorinmolecularsrapidresponsetothecovid19pandemic